tiprankstipranks
scPharmaceuticals announces launch, commercial availability of FUROSCIX
The Fly

scPharmaceuticals announces launch, commercial availability of FUROSCIX

scPharmaceuticals announced the launch and commercial availability of FUROSCIX, a proprietary formulation of furosemide delivered via an on-body infusor for the outpatient treatment of congestion due to fluid overload in adult patients with New York Heart Association Class II and Class III chronic heart failure. FUROSCIX is not indicated for use in emergency situations or in patients with acute pulmonary edema. The FUROSCIX Infusor will deliver only an 80-mg dose. Management will provide an update on this and other recent developments during its regularly scheduled fourth quarter 2022 earnings conference call and webcast in March.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on SCPH:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles